Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 69% of modeled bridge. Strengths: Occupancy Rate, Net-to-Gross Ratio. Risks: Revenue per Bed. Risk-adjusted uplift: $1.0M (vs $1.5M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $558K | $558K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $537K | $15K | $552K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $86K | $254K | $340K | $1.1M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $18K | $18K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 38.3% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $140K | $279K | $419K | $558K | $558K | $558K | $558K |
| Denial Rate Reduction | $0 | $138K | $276K | $414K | $552K | $552K | $552K | $552K |
| A/R Days Reduction | $0 | $113K | $226K | $340K | $340K | $340K | $340K | $340K |
| Clean Claim Rate | $0 | $9K | $18K | $18K | $18K | $18K | $18K | $18K |
| Cumulative | $0 | $400K | $799K | $1.2M | $1.5M | $1.5M | $1.5M | $1.5M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $1.5M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 67% / 13.2x | 72% / 15.0x | 76% / 16.8x | 78% / 17.7x | 79% / 18.6x |
| 9.0x | 63% / 11.3x | 67% / 12.9x | 71% / 14.6x | 73% / 15.4x | 75% / 16.2x |
| 10.0x | 58% / 9.9x | 63% / 11.3x | 66% / 12.8x | 68% / 13.5x | 70% / 14.2x |
| 11.0x | 54% / 8.7x | 59% / 10.0x | 63% / 11.3x | 64% / 12.0x | 66% / 12.7x |
| 12.0x | 50% / 7.7x | 55% / 8.9x | 59% / 10.1x | 61% / 10.7x | 63% / 11.3x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 38% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 4.1x, adding 4.4 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $1.4M | — | $1.4M | 4.9% |
| Year 1 | $1.4M | +$979K | $2.4M | 8.5% |
| Year 2 | $1.4M | +$1.5M | $2.9M | 10.4% |
| Year 3 | $1.5M | +$1.5M | $2.9M | 10.6% |
| Year 4 | $1.5M | +$1.5M | $3.0M | 10.7% |
| Year 5 | $1.6M | +$1.5M | $3.0M | 10.9% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $279K | $419K | $558K | $670K |
| Denial Rate Reductio | $276K | $414K | $552K | $663K |
| A/R Days Reduction | $170K | $255K | $340K | $407K |
| Clean Claim Rate | $9K | $13K | $18K | $21K |
| Total | $734K | $1.1M | $1.5M | $1.8M |
Peer Context — Where This Hospital Sits
Key metrics vs 96 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 4.9% | -18.3% | -0.4% | 8.9% | P59 |
| Net-to-Gross | 11.3% | 18.6% | 30.3% | 38.3% | P0 |
| Occupancy | 61.0% | 35.3% | 56.2% | 71.9% | P59 |
| Rev/Bed | $416K | $406K | $619K | $1.2M | P28 |
| Exp/Bed | $396K | $395K | $827K | $1.3M | P25 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.